Anticancer Drugs Market

Global Market Study on Anticancer Drugs: Targeted Therapy Drug Class Anticipated to Exhibit Highest Revenue Contribution Through 2026

Anticancer Drugs Market Segmented By Cytotoxic, Hormonal Therapy, Monoclonal antibodies, Small molecule inhibitors as Targeted Therapy in Hospital Pharmacies and Retail Pharmacies

- Table of Content -

1. Executive Summary

    1.1. Market Overview

    1.2. Market Analysis

    1.3. PMR Analysis and Recommendations

    1.4. Wheel of Fortune

2. Market Introduction

    2.1. Market Definition

    2.2. Market Taxonomy

3. Anti-Cancer Drugs Market Opportunity Analysis

    3.1. Macro-Economic Factors

    3.2. Opportunity Analysis

4. Market Background

    4.1. Recent Developments

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Trends

    4.3. Reimbursement Landscape

    4.4. Regulatory Scenario

5. Macroeconomic Assumptions

6. Global Economic Outlook

    6.1. Gross Domestic Product by Region & Country, 2006 – 2021

    6.2. Disease Outlook

7. Key Inclusions

    7.1. Epidemiology

    7.2. Pipeline Analysis

    7.3. Mergers and Acquisitions

8. North America Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025

    8.1. Introduction

    8.2. Historical Market Value (US$ Mn) Analysis By Country, 2012–2016

        8.2.1. U.S.

        8.2.2. Canada

    8.3. Market Value (US$ Mn) Forecast By Country, 2017–2025

    8.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016

        8.4.1. Cytotoxics

        8.4.2. Hormonal Therapy

        8.4.3. Targeted Therapy

            8.4.3.1. Monoclonal antibodies

            8.4.3.2. Small molecule inhibitors

    8.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025

    8.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016

        8.6.1. Prostate Cancer

        8.6.2. Lung Cancer

        8.6.3. Breast Cancer

        8.6.4. Melanoma

        8.6.5. Leukemia

        8.6.6. Others

    8.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025

    8.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016

        8.8.1. Hospital Pharmacies

        8.8.2. Retail Pharmacies

    8.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025

    8.10. Market Attractiveness Analysis

        8.10.1. By Country

        8.10.2. By Drug Class

        8.10.3. By Indications

        8.10.4. By Distribution Channels

    8.11. Key Market Participants – Intensity Mapping

    8.12. Drivers and Restraints – Impact Analysis

9. Latin America Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025

    9.1. Introduction

    9.2. Historical Market Value (US$ Mn) Trends Analysis By Country, 2012–2016

        9.2.1. Brazil

        9.2.2. Mexico

        9.2.3. Rest of Latin America

    9.3. Market Value (US$ Mn) Forecast By Country, 2017–2025

    9.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016

        9.4.1. Cytotoxics

        9.4.2. Hormonal Therapy

        9.4.3. Targeted Therapy

            9.4.3.1. Monoclonal antibodies

            9.4.3.2. Small molecule inhibitors

    9.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025

    9.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016

        9.6.1. Prostate Cancer

        9.6.2. Lung Cancer

        9.6.3. Breast Cancer

        9.6.4. Melanoma

        9.6.5. Leukemia

        9.6.6. Others

    9.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025

    9.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016

        9.8.1. Hospital Pharmacies

        9.8.2. Retail Pharmacies

    9.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025

    9.10. Market Attractiveness Analysis

        9.10.1. By Country

        9.10.2. By Drug Class

        9.10.3. By Indications

        9.10.4. By Distribution Channels

    9.11. Key Market Participants – Intensity Mapping

    9.12. Drivers and Restraints – Impact Analysis

10. Europe Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025

    10.1. Introduction

    10.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016

        10.2.1. Germany

        10.2.2. U.K.

        10.2.3. France

        10.2.4. Italy

        10.2.5. Spain

        10.2.6. Russia

        10.2.7. Rest of Europe

    10.3. Market Value (US$ Mn) Forecast By Country, 2017–2025

    10.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016

        10.4.1. Cytotoxics

        10.4.2. Hormonal Therapy

        10.4.3. Targeted Therapy

            10.4.3.1. Monoclonal antibodies

            10.4.3.2. Small molecule inhibitors

    10.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025

    10.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016

        10.6.1. Prostate Cancer

        10.6.2. Lung Cancer

        10.6.3. Breast Cancer

        10.6.4. Melanoma

        10.6.5. Leukemia

        10.6.6. Others

    10.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025

    10.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016

        10.8.1. Hospital Pharmacies

        10.8.2. Retail Pharmacies

    10.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025

    10.10. Market Attractiveness Analysis

        10.10.1. By Country

        10.10.2. By Drug Class

        10.10.3. By Indications

        10.10.4. By Distribution Channels

    10.11. Key Market Participants – Intensity Mapping

    10.12. Drivers and Restraints – Impact Analysis

11. Asia Pacific Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025

    11.1. Introduction

    11.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016

        11.2.1. China

        11.2.2. India

        11.2.3. Australia and NZ

        11.2.4. ASEAN

        11.2.5. Rest of Asia Pacific

    11.3. Market Value (US$ Mn) Forecast By Country, 2017–2025

    11.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016

        11.4.1. Cytotoxics

        11.4.2. Hormonal Therapy

        11.4.3. Targeted Therapy

            11.4.3.1. Monoclonal antibodies

            11.4.3.2. Small molecule inhibitors

    11.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025

    11.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016

        11.6.1. Prostate Cancer

        11.6.2. Lung Cancer

        11.6.3. Breast Cancer

        11.6.4. Melanoma

        11.6.5. Leukemia

        11.6.6. Others

    11.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025

    11.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016

        11.8.1. Hospital Pharmacies

        11.8.2. Retail Pharmacies

    11.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025

    11.10. Market Attractiveness Analysis

        11.10.1. By Country

        11.10.2. By Drug Class

        11.10.3. By Indications

        11.10.4. By Distribution Channels

    11.11. Key Market Participants – Intensity Mapping

    11.12. Drivers and Restraints – Impact Analysis

12. Japan Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025

    12.1. Introduction

    12.2. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016

        12.2.1. Cytotoxics

        12.2.2. Hormonal Therapy

        12.2.3. Targeted Therapy

            12.2.3.1. Monoclonal antibodies

            12.2.3.2. Small molecule inhibitors

    12.3. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025

    12.4. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016

        12.4.1. Prostate Cancer

        12.4.2. Lung Cancer

        12.4.3. Breast Cancer

        12.4.4. Melanoma

        12.4.5. Leukemia

        12.4.6. Others

    12.5. Market Value (US$ Mn) Forecast By Indications, 2017–2025

    12.6. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016

        12.6.1. Hospital Pharmacies

        12.6.2. Retail Pharmacies

    12.7. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025

    12.8. Market Attractiveness Analysis

        12.8.1. By Drug Class

        12.8.2. By Indications

        12.8.3. By Distribution Channels

    12.9. Key Market Participants – Intensity Mapping

    12.10. Drivers and Restraints – Impact Analysis

13. Middle East & Africa Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025

    13.1. Introduction

    13.2. Historical Market Value (US$ Mn) Trend Analysis By Country, 2012–2016

        13.2.1. South Africa

        13.2.2. GCC Countries

        13.2.3. Rest of MEA

    13.3. Market Value (US$ Mn) Forecast By Country, 2017–2025

    13.4. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016

        13.4.1. Cytotoxics

        13.4.2. Hormonal Therapy

        13.4.3. Targeted Therapy

            13.4.3.1. Monoclonal antibodies

            13.4.3.2. Small molecule inhibitors

    13.5. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025

    13.6. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016

        13.6.1. Prostate Cancer

        13.6.2. Lung Cancer

        13.6.3. Breast Cancer

        13.6.4. Melanoma

        13.6.5. Leukemia

        13.6.6. Others

    13.7. Market Value (US$ Mn) Forecast By Indications, 2017–2025

    13.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016

        13.8.1. Hospital Pharmacies

        13.8.2. Retail Pharmacies

    13.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025

    13.10. Market Attractiveness Analysis

        13.10.1. By Country

        13.10.2. By Drug Class

        13.10.3. By Indications

        13.10.4. By Distribution Channels

    13.11. Key Market Participants – Intensity Mapping

    13.12. Drivers and Restraints – Impact Analysis

14. Forecast Factors: Relevance and Impact

15. Forecast Assumptions

16. Competition Analysis

    16.1. Competition Dashboard

    16.2. Company Deep Dive

        16.2.1. F. Hoffmann-La Roche Ltd

            16.2.1.1. Overview

            16.2.1.2. Product and Indications Portfolio

            16.2.1.3. Production Footprint

            16.2.1.4. Sales Footprint

            16.2.1.5. Channel Footprint

            16.2.1.6. Strategy

                16.2.1.6.1. Marketing Strategy

                16.2.1.6.2. Product Strategy

                16.2.1.6.3. Channel Strategy

        16.2.2. Celgene Corp

            16.2.2.1. Overview

            16.2.2.2. Product and Indications Portfolio

            16.2.2.3. Production Footprint

            16.2.2.4. Sales Footprint

            16.2.2.5. Channel Footprint

            16.2.2.6. Strategy

                16.2.2.6.1. Marketing Strategy

                16.2.2.6.2. Product Strategy

                16.2.2.6.3. Channel Strategy

        16.2.3. Novartis AG

            16.2.3.1. Overview

            16.2.3.2. Product and Indications Portfolio

            16.2.3.3. Production Footprint

            16.2.3.4. Sales Footprint

            16.2.3.5. Channel Footprint

            16.2.3.6. Strategy

                16.2.3.6.1. Marketing Strategy

                16.2.3.6.2. Product Strategy

                16.2.3.6.3. Channel Strategy

        16.2.4. Bristol-Myers Squibb Co

            16.2.4.1. Overview

            16.2.4.2. Product and Indications Portfolio

            16.2.4.3. Production Footprint

            16.2.4.4. Sales Footprint

            16.2.4.5. Channel Footprint

            16.2.4.6. Strategy

                16.2.4.6.1. Marketing Strategy

                16.2.4.6.2. Product Strategy

                16.2.4.6.3. Channel Strategy

        16.2.5. Johnson & Johnson

            16.2.5.1. Overview

            16.2.5.2. Product and Indications Portfolio

            16.2.5.3. Production Footprint

            16.2.5.4. Sales Footprint

            16.2.5.5. Channel Footprint

            16.2.5.6. Strategy

                16.2.5.6.1. Marketing Strategy

                16.2.5.6.2. Product Strategy

                16.2.5.6.3. Channel Strategy

        16.2.6. Merck & Co.

            16.2.6.1. Overview

            16.2.6.2. Product and Indications Portfolio

            16.2.6.3. Production Footprint

            16.2.6.4. Sales Footprint

            16.2.6.5. Channel Footprint

            16.2.6.6. Strategy

                16.2.6.6.1. Marketing Strategy

                16.2.6.6.2. Product Strategy

                16.2.6.6.3. Channel Strategy

        16.2.7. Eli Lilly and Company

            16.2.7.1. Overview

            16.2.7.2. Product and Indications Portfolio

            16.2.7.3. Production Footprint

            16.2.7.4. Sales Footprint

            16.2.7.5. Channel Footprint

            16.2.7.6. Strategy

                16.2.7.6.1. Marketing Strategy

                16.2.7.6.2. Product Strategy

                16.2.7.6.3. Channel Strategy

        16.2.8. AstraZeneca plc

            16.2.8.1. Overview

            16.2.8.2. Product and Indications Portfolio

            16.2.8.3. Production Footprint

            16.2.8.4. Sales Footprint

            16.2.8.5. Channel Footprint

            16.2.8.6. Strategy

                16.2.8.6.1. Marketing Strategy

                16.2.8.6.2. Product Strategy

                16.2.8.6.3. Channel Strategy

        16.2.9. Amgen Inc..

            16.2.9.1. Overview

            16.2.9.2. Product and Indications Portfolio

            16.2.9.3. Production Footprint

            16.2.9.4. Sales Footprint

            16.2.9.5. Channel Footprint

            16.2.9.6. Strategy

                16.2.9.6.1. Marketing Strategy

                16.2.9.6.2. Product Strategy

                16.2.9.6.3. Channel Strategy

        16.2.10. Roche Holding AG

            16.2.10.1. Overview

            16.2.10.2. Product and Indications Portfolio

            16.2.10.3. Production Footprint

            16.2.10.4. Sales Footprint

            16.2.10.5. Channel Footprint

            16.2.10.6. Strategy

                16.2.10.6.1. Marketing Strategy

                16.2.10.6.2. Product Strategy

                16.2.10.6.3. Channel Strategy

17. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Region

    17.1. Introduction/Key Findings

    17.2. Historical Market Value (US$ Mn) Trend Analysis By Region, 2012–2016

    17.3. Market Value (US$ Mn) Forecast By Region, 2017–2025

        17.3.1. North America

        17.3.2. Latin America

        17.3.3. Europe

        17.3.4. Asia Pacific

        17.3.5. Middle East & Africa

        17.3.6. China

    17.4. Market Attractiveness Analysis By Region

18. Global Anti-Cancer Drugs Analysis 2012–2016 and Forecast 2017–2025, By Drug Class

    18.1. Introduction/Key Findings

    18.2. Historical Market Value (US$ Mn) Trend Analysis By Drug Class, 2012–2016

        18.2.1. Cytotoxics

        18.2.2. Hormonal Therapy

        18.2.3. Targeted Therapy

            18.2.3.1. Monoclonal antibodies

            18.2.3.2. Small molecule inhibitors

    18.3. Market Value (US$ Mn) Forecast By Drug Class, 2017–2025

    18.4. Market Attractiveness Analysis

19. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Indications

    19.1. Introduction/Key Findings

    19.2. Historical Market Value (US$ Mn) Trend Analysis By Indications, 2012–2016

        19.2.1. Prostate Cancer

        19.2.2. Lung Cancer

        19.2.3. Breast Cancer

        19.2.4. Melanoma

        19.2.5. Leukemia

        19.2.6. Others

    19.3. Market Value (US$ Mn) Forecast By Indications, 2017–2025

    19.4. Market Attractiveness Analysis By Indications

20. Global Anti-cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025, By Distribution Channels

    20.1. Introduction/Key Findings

    20.2. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channels, 2012–2016

        20.2.1. Hospital Pharmacies

        20.2.2. Retail Pharmacies

    20.3. Market Value (US$ Mn) Forecast By Distribution Channels, 2017–2025

    20.4. Market Attractiveness Analysis By Distribution Channels

21. Global Anti-Cancer Drugs Market Analysis 2012–2016 and Forecast 2017–2025

    21.1. Market Value Share Analysis By All Segment

    21.2. Y-o-Y Growth Analysis By All Segment

    21.3. Absolute $ Opportunity

22. Research Methodology

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

- List Of Table -

Table 01A: Funding by Research Areas 2017 (US $Millions)

Table 01A: Funding by Research Areas 2017 (US $Millions)

Table 01B: Funding by Research Areas 2017 (US $Millions)

Table 02A: New Active Substances Launched in 2017 and Summary of Clinical Benefits

Table 02B: New Active Substances Launched in 2017 and Summary of Clinical Benefits

Table 02C: New Active Substances Launched in 2017 and Summary of Clinical Benefits

Table 03: Estimated Number of Deaths for the Four Major Cancers by Sex and Age Group, 2017

Table 04: Estimated New Cases for the Four Major Cancers by Sex and Age Group, 2016

Table 05: Difference in approval times between EMEA and FDA for selected targeted therapies

Table 06: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 8A: Prevalence of Cancer in North America, 2017

Table 8B: Prevalence of Cancer in Latin America, 2017

Table 8C: Prevalence of Cancer in Asia Pacific, 2017

Table 8D: Prevalence of Cancer in Europe, 2017

Table 09: Number of FDA Approvals (2010-2017)

Table 10: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country

Table 11: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

Table 12: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication

Table 13: North America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

Table 14: North America Anticancer Drugs Market Participants Presence (Intensity Mapping)

Table 15: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country

Table 16: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

Table 17: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication

Table 18: Latin America Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

Table 19: North America Anticancer Drugs Market Participants Presence (Intensity Mapping)

Table 20: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country

Table 21: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

Table 22: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication

Table 23: Europe Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

Table 24: Europe Anticancer Drugs Market Participants Presence (Intensity Mapping)

Table 25: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country

Table 26: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

Table 27: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication

Table 28: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

Table 29: Asia Pacific Excluding Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)

Table 30: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

Table 31: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication

Table 32: Japan Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

Table 33: Japan Anticancer Drugs Market Participants Presence (Intensity Mapping)

Table 34: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Country

Table 35: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

Table 36: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indication

Table 37: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channel

Table 38: Middle East and Africa Anticancer Drugs Market Participants Presence (Intensity Mapping)

Table 39A: Competition Dashboard

Table 39B: Competition Dashboard

Table 39C: Competition Dashboard

Table 40: Anticancer Drugs Market Value (US$ Mn) 2013–2017 and Forecast 2018-2026 By Region

Table 41: Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Drug Class

Table 42: Global Anticancer Drugs Market Value Analysis (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Indications

Table 43: Global Anticancer Drugs Market Value (US$ Mn) Analysis 2013-2017 and Forecast 2018-2026, By Distribution Channels

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

- List Of Chart -

Figure 01: Global Anticancer Drugs Market Value Share By Drug Class (2018 E)

Figure 02: Global Anticancer Drugs Market Value Share By Indications (2018 E)

Figure 03: Global Anticancer Drugs Market Value Share By Distribution Channel (2018 E)

Figure 04: Global Anticancer Drugs Market Value Share By Regions (2018 E)

Figure 05: New Cancer Drugs Approved Each Year

Figure 06: Growth of the Late Phase Oncology Pipeline, 2005-2015

Figure 07: The Global Late Phase Oncology Pipeline in 2015

Figure 08: Estimates Of National Expenditures For Cancer Care (In Billions Of Dollars) By Cancer Site And Year

Figure 09: Availability of 55 Oncology Medicines First Launched Globally 2012—2016

Figure 10: Number of FDA approved pharmaceuticals (2010-2017)

Figure 11: North America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 12: North America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 13: Canada Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 14: U.S. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 15: Canada Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 16: U.S. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 17: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 18: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 19: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 20: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 21: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 22: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 23: North America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026

Figure 24: North America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)

Figure 25: North America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026

Figure 26: North America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026

Figure 27: Latin Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 28: Latin Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 29: Mexico Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 30: Brazil Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 31: Mexico Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 32: Brazil Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 33: Rest of Latin America Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 34: Rest of Latin America Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 35: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 36: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 37: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 38: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 39: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 40: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 41: Latin America Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026

Figure 42: Latin America Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026

Figure 43: Latin America Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026

Figure 44: Latin America Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026

Figure 45: Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 46: Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 47: Germany Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 48: U.K. Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 49: Germany Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 50: U.K. Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 51: Italy Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 52: France Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 53: Italy Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 54: France Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 55: Russia Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 56: Spain Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 57: Russia Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 58: Spain Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 59: Rest of Europe Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 60: Rest of Europe Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 61: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 62: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 63: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 64: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 65: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 66: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 67: Europe Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026

Figure 68: Europe Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026

Figure 69: Europe Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026

Figure 70: Europe Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026

Figure 71: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 72: Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 73: India Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 74: China Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 75: India Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 76: China Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 77: ASEAN Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 78: Australia and NZ Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 79: ASEAN Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 80: Australia and NZ Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 81: Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 82: Rest of Asia Pacific Excluding Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 83: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 84: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 85: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 86: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 87: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 88: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 89: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026

Figure 90: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026

Figure 91: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026

Figure 92: Asia Pacific Excluding Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026

Figure 93: Japan Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 94: Japan Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 95: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 96: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 97: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 98: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 99: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 100: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 101: Japan Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026

Figure 102: Japan Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026 (US$ Mn)

Figure 103: Japan Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026

Figure 104: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 105: Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 106: GCC Countries Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 107: South Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 108: GCC Countries Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 109: South Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 110: Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 111: Rest of Middle East and Africa Anticancer Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 112: Hormonal Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 113: Cytotoxics Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 114: Hormonal Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 115: Cytotoxics Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 116: Targeted Therapy Drugs Market Value (US$ Mn) Analysis, 2013–2017

Figure 117: Targeted Therapy Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2018–2026

Figure 118: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Country, 2018-2026

Figure 119: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Indication, 2018-2026

Figure 120: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Distribution Channel, 2018-2026

Figure 121: Middle East and Africa Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018-2026

Figure 122: Revenue Contribution by Tier Type

Figure 123: Global Anticancer Drugs Market Structure

Figure 124: Global Anticancer Drugs Market Share Analysis (%) By Region, 2018 & 2026

Figure 125: Global Anticancer Drugs Market Y-o-Y Growth (%) By Region, 2017–2026

Figure 126: Global Anticancer Drugs Market Attractiveness Analysis By Region, 2018–2026

Figure 127: Global Anticancer Drugs Market Share

Figure 128: Anticancer Drugs Market Y-o-Y Growth (%) By Drug Class, 2017–2026

Figure 129: Global Anticancer Drugs Market Attractiveness Analysis By Drug Class, 2018–2026

Figure 130: Global Anticancer Drugs Market Share

Figure 131: Anticancer Drugs Market Y-o-Y Growth (%) By Indications, 2017–2026

Figure 132: Global Anticancer Drugs Market Attractiveness Analysis By Indications, 2018–2026

Figure 133: Global Anticancer Drugs Market Share Analysis (%) By Distribution Channels, 2018 & 2026

Figure 134: Global Anticancer Drugs Market

Figure 135: Global Anticancer Drugs Market Attractiveness Analysis By Distribution Channels, 2018–2026

Figure 136: Global Anticancer Drugs Market Value Analysis and Forecast, 2017–2026 (US$ Mn)

Figure 137: Global Anticancer Drugs Market Absolute $ Opportunity (US$ Mn), 2017–2026

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate